Becton Dickinson achieves a 90% customer satisfaction rate

in the survey

Most of our customers are satisfied with the ordering and supply system items

Becton Dickinson (BD Korea), a multinational medical device and equipment manufacturing company, achieved a customer satisfaction rate of 90%.

 

The company conducted a customer satisfaction survey for domestic pharmaceutical and bio customers and announced the results on the 6th.

 

The survey was conducted between January 9 and February 3 of this year for a total of 74 domestic pharmaceutical and bio customers that supply drug delivery systems including pre-filled syringes from the BD Pharmaceutical Division.

 

It was conducted online for about a month until the day.

 

The survey consisted of a total of 25 questions in five areas: product ordering and delivery, quality and technical support, understanding customer needs, prospects for partnerships, and online resources.

 

As a result of the survey, more than 90% of customers responded that they were satisfied with BD Korea's order, delivery, and supply system.

 

Out of BD Korea's services, items of interest were answered in the order of ▲approval support (31.52%) ▲container tightness test (25.0%) ▲device, and drug convergence product test (22.83%).

 

BD Korea provides customized permit support services optimized for each country's regulations, requirements, and guidelines in various countries including Korea, Europe, the United States, China, and Malaysia.

 

Representatively, there are RA services (Regulatory Support Service), which supports convergence product registration, and Your Path (BD YourPathTM), which provides product and test permit consulting online and offline.

 

BD Korea merged with ZebraSci Inc., a company specializing in convergence product testing, in 2021 to provide various service items from the initial development stage of customers' products to clinical and commercialization.

 

Through this, BD Korea has expanded its capabilities to smoothly support customers' goals and timely market entry during the development of convergence products.

 

In addition, in a survey of innovative drug delivery system products and service solutions, ▲ technology that enables product traceability (30.82%) ▲ wearable devices for injection (29.56%) ▲ reusable autoinjectors (18.87%) were the main areas of interest for customers.

 

appear.

 

In addition, as a result of a satisfaction survey on BD Korea's technical support, data provision, and quality policy, it was tallied that more than 80% were satisfied.

 

BD Korea plans to hold a professional consulting meeting with a BD Global license support manager for pre-booked customers at the International Pharmaceutical, Bio, and Cosmetics Technology Exhibition (COPHEX), which will be held from April 18 to 21 this year.